Healthcare
Intellia Therapeutics, Inc.(NTLA)
Live Price
Offline$15.67
+3.09% today
1Y Change
+63.06%
Window
Jun 26, 2025 โ Jun 18, 2026
- Market Cap
- $1.57B
- Revenue Growth
- +16.9%
- EPS Growth
- +27.4%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 26, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Intellia Therapeutics, Inc. (NTLA) is a Healthcare stock with a market cap of $1.57B and listed on NASDAQ. The stock last traded around $15.67 and up 63.1% across the available one-year price window (Jun 26, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +16.9%, EPS growth of +27.4%, a dividend yield of 0.0%. What stands out right now is revenue +16.9%, EPS +27.4%, free cash flow 0.0% with operating margin -651.7% and ROIC -57.7%. Valuation already assumes a fairly strong business story at price/sales 23.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines NTLA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+16.9% vs +7.6% peer median
Operating Margin
Below sector median
-651.7% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +16.9% and EPS at +27.4%, with operating margin around -651.7%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -14.3% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | +4.4% | -5.5% | -7.5% |
2026 Feb 26, 2026 | +16.2% | -3.5% | -7.9% | -7.3% |
2025 Nov 6, 2025 | +9.8% | -22.7% | -29.6% | -22.0% |
Benchmark Edge
NTLA vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NTLA
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NTLA Max Drawdown
-71.27%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for NTLA and SPY.
Company Overview
Intellia Therapeutics, Inc.
NASDAQ Global Market
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
- Leadership
- John Leonard
- IPO Date
- May 6, 2016
- Employees
- 403
- Street Address
- 40 Erie Street
- Mailing
- Cambridge, MA, 02139
- Region
- Cambridge, MA, US
- Reporting Currency
- USD
- Investor Line
- 857 285 6200
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 23.1
- Price/Book
- 2.1
Growth
- Revenue
- +16.9%
- EPS
- +27.4%
- Free Cash Flow
- 0.0%
Profitability
- Gross Margin
- -25.6%
- Operating Margin
- -651.7%
- Net Margin
- -609.9%
- ROE
- -56.6%
- ROIC
- -57.7%
Balance Sheet
- Debt/Equity
- 0.14
- Current Ratio
- 5.08
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.